Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q5RI15
UPID:
COX20_HUMAN
Alternative names:
-
Alternative UPACC:
Q5RI15; Q8WV86
Background:
Cytochrome c oxidase assembly protein COX20, mitochondrial, is pivotal for the assembly of mitochondrial respiratory chain complex IV (CIV), also known as cytochrome c oxidase. It functions as a chaperone during the early stages of cytochrome c oxidase subunit II maturation, facilitating the integration of the mature subunit into the CIV holoenzyme.
Therapeutic significance:
The protein is linked to Mitochondrial complex IV deficiency, nuclear type 11, a disorder marked by cerebellar ataxia, dystonia, and increased serum lactate levels. Understanding the role of Cytochrome c oxidase assembly protein COX20 could open doors to potential therapeutic strategies for this mitochondrial disorder.